Scotiabank analyst George Farmer initiated coverage of Mirati Therapeutics with an Underperform rating and $20 price target. The analyst thinks the market opportunity for Mirati’s lead asset, adagrasib, is much more limited than implied by Street estimates. The firm sees the market shrinking as a better understanding and awareness grows of bypass mutations in KRAS and other proteins that predict lack of G12C inhibitor response.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MRTX:
- Mirati Therapeutics price target lowered to $60 from $104 at Guggenheim
- Mirati Therapeutics price target lowered to $45 from $51 at B. Riley
- Mirati Therapeutics price target lowered to $46 from $54 at BofA
- Mirati Therapeutics price target lowered to $71 from $75 at Barclays
- Mirati announces EMA’s CHMP issued negative opinion on MAA for KRAZATI